Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
50%
Acute Decompensated Heart Failure
12%
All-cause Mortality
12%
Amendment Rate
12%
B-type Natriuretic Peptide
12%
Baseline Characteristics
12%
Body Mass Index
12%
Cardiovascular Mortality
25%
Characteristic Event
12%
Clinical Trials
100%
Coronary Artery Disease
25%
Diabetes
12%
Eastern Europe
12%
Estimated Glomerular Filtration Rate
12%
Event Rate
50%
Event-driven Trials
12%
Exclusion Criteria
100%
Expected Impact
12%
Global Events
12%
Hazard Ratio
50%
Heart Failure
100%
Heart Failure Hospitalization
37%
Heart Failure Trials
50%
High Event Rate
12%
High Heart Rate
12%
History of Heart Failure
12%
Left Ventricular Ejection Fraction
25%
Major Bleeding
12%
Mortality Hazard
12%
Myocardial Infarction
25%
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)
12%
Natriuretic Peptides
100%
Neutral Effects
12%
Patient Characteristics
12%
Patient-centered
12%
Peptide-based
100%
Plasma Concentration
12%
Protocol Amendments
62%
Rate Effect
12%
Regional Variation
12%
Risk of Death
12%
Risk Reduction
12%
Rivaroxaban
37%
Selection Criteria
12%
Treatment Effect
25%
Trial Protocol
25%
Medicine and Dentistry
Amino Terminal Sequence
8%
Apoplexy
16%
Body Mass Index
8%
Brain Natriuretic Peptide
8%
Cardiovascular System
16%
Clinical Trial
100%
Congestive Heart Failure
100%
Coronary Artery Disease
16%
Decompensated Heart Failure
8%
Diabetes
8%
Glomerular Filtration Rate
8%
Hazard Ratio
33%
Heart Left Ventricle Ejection Fraction
16%
Major Bleeding
8%
Myocardial Infarction
16%
Natriuretic Factor
100%
Patient Characteristics
8%
Rivaroxaban
25%
Treatment Effect
16%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Natriuretic Peptide
7%
Cerebrovascular Accident
15%
Clinical Trial
100%
Congestive Heart Failure
100%
Coronary Artery Disease
15%
Heart Infarction
15%
Natriuretic Factor
100%
Rivaroxaban
23%
Biochemistry, Genetics and Molecular Biology
Blood Plasma
11%
Body Mass
11%
Brain Natriuretic Peptide
11%
Clinical Trial
100%
Coronary Artery Disease
22%
Heart Left Ventricle Ejection Fraction
22%
N-Terminus
11%
Natriuretic Peptide
100%
Rivaroxaban
33%